Fondazione S. Maugeri IRCCS
Welcome,         Profile    Billing    Logout  
 11 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ciccarese, Mariangela
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32
Bernardo, Antonio
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Active, not recruiting
3
405
Europe
Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy
ETOP IBCSG Partners Foundation, Pfizer
Breast Cancer Recurrent
01/26
01/29
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ciccarese, Mariangela
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32
Bernardo, Antonio
POLAR, NCT03820830 / 2018-003553-19: Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Active, not recruiting
3
405
Europe
Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy
ETOP IBCSG Partners Foundation, Pfizer
Breast Cancer Recurrent
01/26
01/29
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32

Download Options